Core Insights - AstraZeneca and Ionis Pharmaceuticals have jointly developed Ipupronit Sodium Injection, which has been approved by the National Medical Products Administration for the treatment of adult patients with hereditary transthyretin amyloidosis polyneuropathy (ATTRv-PN) [1] - Ipupronit Sodium is the first and currently the only gene-silencing agent approved for the treatment of ATTRv-PN in China [1] Group 1: Disease Overview - ATTR is caused by the accumulation of misfolded TTR protein produced by the liver, leading to organ damage and failure, with various complications affecting cardiovascular, neurological, and renal health [2] - ATTR has multiple phenotypes, including ATTR-CM (primarily affecting the heart) and ATTRv-PN (primarily affecting the peripheral nervous system), with ATTRv-PN being a debilitating disease that can lead to motor function impairment within five years of diagnosis [2] - The average age of onset for patients in China is 42 years, with a range from 17 to 68 years, and there is a significant delay of 3 to 4 years from symptom onset to diagnosis due to low awareness among the public and healthcare professionals [2] Group 2: Treatment Insights - Ipupronit Sodium is a gene-silencing agent administered once a month, which works by upstream inhibition of TTR protein production, showing potential for treating various types of transthyretin amyloidosis [3] - The approval of Ipupronit Sodium provides new hope for ATTRv-PN patients, as clinical evidence indicates it can halt the progression of neuropathy and significantly improve neurological function and quality of life [3]

Core Viewpoint - The approval of Wainua® (eplontersen) by AstraZeneca and Ionis for the treatment of ATTRv-PN in China represents a significant advancement in addressing a previously underserved medical need for patients suffering from this debilitating disease [1] Group 1: Product Approval - Wainua® is the first and currently the only gene-silencing agent approved in China for the treatment of ATTRv-PN [1] - The drug was officially approved on December 22, 2025, marking a milestone in the treatment options available for patients [1] Group 2: Disease Impact - ATTRv-PN is a debilitating disease that can lead to peripheral nerve damage, with patients typically experiencing motor function impairment within five years of diagnosis and a general mortality rate within ten years if untreated [1] - The disease has been included in China's second batch of rare disease catalog, highlighting its significance and the need for effective treatments [1] Group 3: Expert Commentary - Professor Zhang Shuyang, the chief researcher of EPIC-ATTR in China, emphasized the long-standing impact of ATTRv-PN on patients' neurological symptoms and quality of life, noting the limited treatment options available prior to the approval of Wainua® [1]